[ad_1]
Meet the Suspicious 8: Dividends Over 6% With Plenty of Problems
[ad_2]
[ad_1]
Verizon mobile phone customers could share a proposed $100 million class action settlement over monthly fees that people suing the communications company claim were unfairly charged and improperly disclosed. But those who want to claim their share of that money need to act by April 15.
Continue reading this article with a Barron’s subscription.
View Options[ad_1]
The Russell 2000 Index soared 12% in December, which might reflect investors’ exuberance about the state of the U.S. economy — it appears the Federal Reserve has won its battle against inflation.
But if you are looking to broaden your exposure to the stock market beyond the large-cap S&P 500
SPX,
buying shares of a fund that tracks the Russell 2000 Index
RUT
might not be the best way to do it. This is because the Russell 2000 isn’t selective — it is made up of the smallest 2,000 companies by market capitalization in the Russell 3000 Index
RUA,
which itself is designed to capture about 98% of the U.S. public equity market.
A better choice might be the S&P Small Cap 600 Index
SML
because S&P Global requires companies to show four consecutive quarters of profitability to be initially included in the index, among other criteria.
Below is a screen of analysts’ favorite stocks among the S&P Small Cap 600, along with another for the Russell 2000.
Much of the small-cap buying in December might have resulted from covering of short positions by hedge-fund managers. This idea is backed by the timing of trading activity immediately following the Federal Open Market Committee’s announcement on Dec. 13 that it wouldn’t change its interest-rate policy, according to MacroTourist blogger Kevin Muir. The Fed’s economic projections released the same day also indicate three cuts to the federal-funds rate in 2024.
Heading into the end of the year, a fund manager who had shorted small-caps, and then was surprised by the Fed’s interest-rate projections, might have scrambled to buy stocks it had shorted to close-out the positions and hopefully lock in gains, or limit losses.
That buying activity and resulting pop in small-cap prices could set up a typical “head fake” for investors as the new year begins, according to Muir.
Looking at data for companies’ most recently reported fiscal quarters, 58% of the Russell 2000 reported positive earnings per share, according to data provided by FactSet. In other words, hundreds of these companies were losing money. These might include promising companies facing “binary events,” such as make-or-break drug trials in the biotechnology industry.
In comparison, 78% of companies among the S&P Small Cap 600 were profitable, and 93% of the S&P 500 were in the black.
Here are long-term performance figures for exchange-traded funds that track all three indexes:
| ETF | Ticker | 2023 | 3 years | 5 years | 10 years | 15 years | 20 years |
| iShares Russell 2000 ETF | IWM | 17% | 7% | 61% | 99% | 428% | 365% |
| iShares Core S&P Small Cap ETF | IJR | 16% | 25% | 69% | 129% | 540% | 515% |
| SPDR S&P 500 ETF Trust | SPY | 26% | 34% | 108% | 210% | 629% | 527% |
| Source: FactSet | |||||||
An approach tracking the S&P Small Cap 600 has outperformed the Russell 2000 for all periods, with margins widening as you go further back.
Brett Arends: You own the wrong small-cap fund. How to get into a better one.
For the first screen, we began with the S&P Small Cap 600 and narrowed the list to 385 companies covered by at least five analysts polled by FactSet. Then we cut the list to 92 companies with “buy” or equivalent ratings among at least 75% of the covering analysts.
Here are the 20 remaining stocks among the S&P Small Cap 600 with the highest 12-month upside potential indicated by analysts’ consensus price targets:
| Company | Ticker | Share “buy” ratings | Dec. 29 price | Consensus price target | Implied 12-month upside potential |
| Vir Biotechnology Inc. |
VIR, |
88% | $10.06 | $32.00 | 218% |
| Arcus Biosciences Inc. |
RCUS, |
82% | $19.10 | $41.00 | 115% |
| Xencor Inc. |
XNCR, |
92% | $21.23 | $39.83 | 88% |
| Dynavax Technologies Corp. |
DVAX, |
100% | $13.98 | $24.80 | 77% |
| ModivCare Inc. |
MODV, |
100% | $43.99 | $75.50 | 72% |
| Xperi Inc |
XPER, |
80% | $11.02 | $18.20 | 65% |
| Thryv Holdings Inc. |
THRY, |
100% | $20.35 | $32.75 | 61% |
| Ligand Pharmaceuticals Inc. |
LGND, |
100% | $71.42 | $114.80 | 61% |
| Green Plains Inc. |
GPRE, |
80% | $25.22 | $40.30 | 60% |
| Patterson-UTI Energy Inc. |
PTEN, |
75% | $10.80 | $17.00 | 57% |
| Ironwood Pharmaceuticals Inc. Class A |
IRWD, |
83% | $11.44 | $17.83 | 56% |
| Catalyst Pharmaceuticals Inc. |
CPRX, |
100% | $16.81 | $26.20 | 56% |
| Payoneer Global Inc. |
PAYO, |
100% | $5.21 | $8.00 | 54% |
| Helix Energy Solutions Group Inc. |
HLX, |
83% | $10.28 | $15.00 | 46% |
| Arlo Technologies Inc. |
ARLO, |
100% | $9.52 | $13.80 | 45% |
| Pacira Biosciences Inc. |
PCRX, |
100% | $33.74 | $48.40 | 43% |
| Privia Health Group Inc. |
PRVA, |
100% | $23.03 | $32.53 | 41% |
| Semtech Corp. |
SMTC, |
92% | $21.91 | $30.90 | 41% |
| Talos Energy Inc. |
TALO, |
78% | $14.23 | $20.00 | 41% |
| Digi International Inc. |
DGII, |
100% | $26.00 | $36.14 | 39% |
| Source: FactSet | |||||
Any stock screen should only be considered a starting point. You should do your own research to form your own opinion before making any investment. one way to begin is by clicking on the tickers for more about each company.
Moving on to the Russell 2000, when we narrowed this group to stocks covered by at least five analysts polled by FactSet, we were left with 936 companies. Among these, 355 have “buy” or equivalent ratings among at least 75% of the covering analysts.
Among those 355 stocks in the Russell 2000, these 20 have the highest implied upside over the next year, based on consensus price targets:
| Company | Ticker | Share “buy” ratings | Dec. 29 price | Consensus price target | Implied 12-month upside potential |
| Karyopharm Therapeutics Inc. |
KPTI, |
75% | $0.87 | $6.00 | 594% |
| Rallybio Corp. |
RLYB, |
100% | $2.39 | $16.50 | 590% |
| Vor Biopharma Inc. |
VOR, |
100% | $2.25 | $15.44 | 586% |
| Tenaya Therapeutics Inc. |
TNYA, |
100% | $3.24 | $19.14 | 491% |
| Compass Therapeutics Inc. |
CMPX, |
86% | $1.56 | $9.17 | 488% |
| Vigil Neuroscience Inc. |
VIGL, |
88% | $3.38 | $18.75 | 455% |
| Trevi Therapeutics Inc. |
TRVI, |
100% | $1.34 | $7.33 | 447% |
| Inozyme Pharma Inc. |
INZY, |
100% | $4.26 | $21.00 | 393% |
| Gritstone bio Inc. |
GRTS, |
100% | $2.04 | $10.00 | 390% |
| Actinium Pharmaceuticals Inc. |
ATNM, |
83% | $5.08 | $23.36 | 360% |
| Lineage Cell Therapeutics Inc. |
LCTX, |
86% | $1.09 | $4.83 | 343% |
| Century Therapeutics Inc. |
IPSC, |
86% | $3.32 | $14.67 | 342% |
| Acrivon Therapeutics Inc. |
ACRV, |
100% | $4.92 | $21.13 | 329% |
| Avidity Biosciences Inc. |
RNA, |
100% | $9.05 | $37.50 | 314% |
| Longboard Pharmaceuticals Inc. |
LBPH, |
100% | $6.03 | $24.17 | 301% |
| Omega Therapeutics Inc. |
OMGA, |
100% | $3.01 | $12.00 | 299% |
| Allogene Therapeutics Inc. |
ALLO, |
82% | $3.21 | $12.79 | 298% |
| X4 Pharmaceuticals Inc. |
XFOR, |
86% | $0.84 | $3.26 | 289% |
| Caribou Biosciences Inc. |
CRBU, |
89% | $5.73 | $22.25 | 288% |
| Stoke Therapeutics Inc. |
STOK, |
78% | $5.26 | $19.33 | 268% |
| Source: FactSet | |||||
That’s right — this Russell 2000 list is all biotech. And in case you are wondering if any companies are on both lists, the answer is no.
Don’t miss: 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
[ad_2]

[ad_1]
By Najat Kantouar
Vodafone Group has reiterated its full-year guidance as it reported a much lower pretax profit for the first half of fiscal 2024, reflecting adverse foreign-exchange rate movements and business disposals in the prior year.
The U.K. telecommunications company said Tuesday that it expects to report underlying earnings before interest, taxes, depreciation, amortization and lease expenses of 13.3 billion euros ($14.23 billion) for the year ending March 31 compared with EUR14.7 billion in fiscal 2023. Adjusted free cash is seen at around EUR3.3 billion, from EUR4.84 billion.
Pretax profit for the six months ended Sept. 30 was EUR550 million compared with EUR1.69 billion for the same period a year earlier.
Adjusted earnings before interest, taxes, depreciation, amortization and lease expenses–which strips out exceptional and other one-off items–was EUR6.39 billion compared with EUR7.24 billion with organic growth of 0.3% despite a significant increase in energy costs.
Adjusted free cash outflow widened to EUR1.47 billion from EUR513 million, reflecting a fall in adjusted Ebitda after leases in the period, together with lower dividends from associates and joint ventures.
Group revenue fell to EUR21.94 billion from EUR22.93 billion despite service revenue growth in both Europe, excluding Turkey, and Africa by 1.5% and 9.0%, respectively.
The board declared an interim dividend of 4.50 European cents for the period, flat on year.
“During the first half of the year, we have delivered improved revenue growth in nearly all of our markets and have returned to growth in Germany in the second quarter. We have also announced transactions to strengthen our position in the U.K. and exit the challenging Spanish market in order to right-size our portfolio for growth.” Chief Executive Officer Margherita Della Valle said.
Write to Najat Kantouar at najat.kantouar@wsj.com
[ad_2]

[ad_1]
By Joe Hoppe
Altice UK said Tuesday that it has purchased a further 650 million shares in BT Group for around 961 million pounds ($1.20 billion), bringing its ownership up to around 24.5% of the company’s issued share capital.
The telecommunications and mass media company said it has restated its position to the board of BT that it doesn’t plan to make an offer for the company and will be bound by that statement under U.K. takeover rules.
Based on BT’s closing share price of 147.85 pence on Monday, this implies Altice’s new purchase is worth around GBP961 million. Its full stake is now worth around GBP3.60 billion.
Write to Joe Hoppe at joseph.hoppe@wsj.com
[ad_2]
[ad_1]
Things move quickly in the world of artificial intelligence. It is easy to sit back and complain about developments that could be disruptive, but sometimes investors are best served by putting emotions aside and observing new developments and how they affect markets. Could AI developments and related trends make you a lot of money?
Below is a new screen showing a group of AI-oriented companies expected to increase their sales most rapidly through 2025, based on consensus estimates among analysts polled by FactSet. Then we show expected revenue growth rates for the largest AI-oriented companies in the screen.
Over the long haul, many businesses might perform more efficiently by employing AI. Maybe this technology can create an economic revolution similar to the one that moved the majority of the working population away from agricultural labor during the 19th and 20th centuries.
Back in February, we screened 96 stocks held by five exchange-traded funds focused on AI and related industries and listed the 20 that analysts thought would rise the most over the following 12 months.
Three months is a long time for AI, and the shakeout hasn’t even started.
Read: Congress and tech seem open to regulating AI efforts, but that doesn’t mean it will happen
There is no way to predict how politicians will react to perceived or real threats of AI and machine learning. And the largest U.S. tech players are doing everything they can to employ the new technology and remain dominant. But that doesn’t mean they will grow more quickly than smaller AI-focused players.
Once again we will begin a screen with these five ETFs:
Altogether and removing duplicates, the five ETFs hold 270 stocks of companies in 23 countries. We first narrowed the list to 197 covered by at least nine analysts and for which consensus sales estimates are available through calendar 2025. We used calendar-year estimates because some companies have fiscal years that don’t match the calendar.
Here are the 20 screened AI-related companies expected by analysts to have the highest compound annual growth rates (CAGR) for sales from 2023 through 2025. Sales estimates are in millions of U.S. dollars. The list also shows which of the above five ETFs holds each stocks.
| Company | Ticker | Estimated sales – 2023 ($mil) | Estimated sales – 2024 ($mil) | Estimated sales – 2025 ($mil) | Two-year estimated sales CAGR through 2025 | Held by |
| BioXcel Therapeutics Inc. |
BTAI, |
$5 | $39 | $121 | 411.5% | WTAI |
| Luminar Technologies Inc. Class A |
LAZR, |
$86 | $266 | $588 | 161.0% | ROBT, WTAI |
| BlackBerry Ltd. |
BB, |
$685 | $769 | $1,925 | 67.6% | ROBT |
| Credo Technology Group Holding Ltd. |
CRDO, |
$183 | $259 | $363 | 40.9% | IRBO |
| SentinelOne Inc. Class A |
S, |
$619 | $881 | $1,176 | 37.9% | WTAI |
| Wolfspeed Inc. |
WOLF, |
$982 | $1,323 | $1,860 | 37.6% | WTAI |
| SK hynix Inc. |
000660, |
$18,319 | $27,899 | $34,542 | 37.3% | WTAI |
| Mobileye Global Inc. Class A |
MBLY, |
$2,109 | $2,782 | $3,920 | 36.3% | ROBT, WTAI |
| Snowflake Inc. Class A |
SNOW, |
$2,811 | $3,863 | $5,139 | 35.2% | IRBO, THNQ, WTAI |
| Lemonade Inc. |
LMND, |
$395 | $471 | $712 | 34.2% | THNQ, WTAI |
| Nio Inc. ADR Class A |
NIO, |
$11,874 | $16,733 | $21,304 | 33.9% | ROBT |
| Stem Inc. |
STEM, |
$607 | $833 | $1,055 | 31.8% | WTAI |
| Upstart Holdings Inc. |
UPST, |
$547 | $768 | $938 | 31.0% | BOTZ, WTAI |
| Cloudflare Inc. Class A |
NET, |
$1,284 | $1,669 | $2,194 | 30.7% | THNQ |
| Samsara Inc. Class A |
IOT, |
$830 | $1,062 | $1,364 | 28.2% | THNQ |
| Ambarella Inc. |
AMBA, |
$287 | $355 | $472 | 28.2% | IRBO, ROBT, THNQ, WTAI |
| iflytek Co. Ltd. Class A |
002230, |
$3,561 | $4,582 | $5,851 | 28.2% | THNQ |
| Tesla Inc. |
TSLA, |
$99,558 | $128,412 | $161,061 | 27.2% | ROBT, THNQ, WTAI |
| CrowdStrike Holdings Inc. Class A |
CRWD, |
$2,935 | $3,793 | $4,739 | 27.1% | THNQ, WTAI |
| PB Fintech Ltd. |
543390, |
$358 | $462 | $573 | 26.5% | IRBO |
| Source: FactSet | ||||||
Click the tickers for more about each company or ETF.
Click here for Tomi Kilgore’s detailed guide to the wealth of information for free on the MarketWatch quote pages.
We have screened for expected revenue growth, rather than for earnings or cash flow, because in a newer tech-oriented business area, investors are most likely to consider the top line as companies sacrifice profits to build market share.
It is important to do your own research if you consider purchasing any individual stock, to form your own opinion about a company’s ability to remain competitive over the long term. Starting from the top of the list, BioXcel Therapeutics Inc.
BTAI,
is expected to show exponential sales growth, but that is from a low expected baseline this year.
What about the largest AI-related companies held by these ETFs?
Here are the largest 20 companies in the screen by market capitalization, ranked by expected sales CAGR from 2022 through 2025. Once again the sales estimates are in millions of U.S. dollars, but the market caps are in billions.
| Company | Ticker | Estimated sales – 2023 ($mil) | Estimated sales – 2024 ($mil) | Estimated sales – 2025 $mil) | Two-year estimated sales CAGR through 2025 | Market Cap ($bil) | Held by |
| Tesla Inc. |
TSLA, |
$99,558 | $128,412 | $161,061 | 27.2% | $528 | ROBT, THNQ, WTAI |
| Nvidia Corp. |
NVDA, |
$29,839 | $36,877 | $46,154 | 24.4% | $722 | BOTZ, IRBO, ROBT, THNQ, WTAI |
| Taiwan Semiconductor Manufacturing Co. Ltd. ADR |
TSM, |
$71,434 | $86,284 | $101,112 | 19.0% | $445 | ROBT, WTAI |
| Advanced Micro Devices Inc. |
AMD, |
$22,976 | $26,823 | $30,359 | 15.0% | $163 | IRBO, ROBT, THNQ, WTAI |
| ASML Holding NV ADR |
ASML, |
$28,974 | $32,374 | $37,796 | 14.2% | $263 | THNQ, WTAI |
| Microsoft Corp. |
MSFT, |
$223,438 | $251,028 | $282,397 | 12.4% | $2,318 | IRBO, ROBT, THNQ, WTAI |
| Samsung Electronics Co. Ltd. |
005930, |
$200,595 | $227,286 | $252,129 | 12.1% | $292 | IRBO, WTAI |
| Amazon.com Inc. |
AMZN, |
$559,438 | $626,549 | $702,395 | 12.1% | $1,164 | IRBO, ROBT, THNQ, WTAI |
| Adobe Inc. |
ADBE, |
$19,470 | $21,784 | $24,276 | 11.7% | $158 | IRBO, THNQ |
| Netflix Inc. |
NFLX, |
$33,915 | $38,067 | $42,275 | 11.6% | $148 | IRBO, THNQ |
| Tencent Holdings Ltd. |
700, |
$88,727 | $99,212 | $110,556 | 11.6% | $422 | IRBO, ROBT |
| Salesforce Inc. |
CRM, |
$34,392 | $38,273 | $42,786 | 11.5% | $205 | IRBO, THNQ |
| Alphabet Inc. Class A |
GOOGL, |
$299,810 | $333,077 | $369,195 | 11.0% | $710 | IRBO, ROBT, THNQ, WTAI |
| Intel Corp. |
INTC, |
$51,060 | $57,799 | $62,675 | 10.8% | $122 | IRBO, ROBT |
| Meta Platforms Inc. Class A |
META, |
$125,901 | $139,545 | $154,259 | 10.7% | $528 | IRBO, WTAI |
| Alibaba Group Holding Ltd. ADR |
BABA, |
$134,140 | $148,206 | $162,199 | 10.0% | $235 | ROBT, THNQ |
| Texas Instruments Inc. |
TXN, |
$17,941 | $19,433 | $20,799 | 7.7% | $148 | IRBO |
| Apple Inc. |
AAPL, |
$390,845 | $416,761 | $445,956 | 6.8% | $2,706 | IRBO, WTAI |
| Siemens Aktiengesellschaft |
SIE, |
$84,681 | $89,145 | $93,925 | 5.3% | $130 | ROBT |
| Johnson & Johnson |
JNJ, |
$98,761 | $100,990 | $103,870 | 2.6% | $414 | ROBT |
| Source: FactSet | |||||||
Tech-stock picks that are small and focused: This fund invests in unsung innovators. Here are 2 top choices.
[ad_2]